CU20200032A7 - Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer - Google Patents
Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncerInfo
- Publication number
- CU20200032A7 CU20200032A7 CU2020000032A CU20200032A CU20200032A7 CU 20200032 A7 CU20200032 A7 CU 20200032A7 CU 2020000032 A CU2020000032 A CU 2020000032A CU 20200032 A CU20200032 A CU 20200032A CU 20200032 A7 CU20200032 A7 CU 20200032A7
- Authority
- CU
- Cuba
- Prior art keywords
- vaccine compositions
- nano
- cancer
- treatment
- particles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 239000001506 calcium phosphate Substances 0.000 title 1
- 235000011010 calcium phosphates Nutrition 0.000 title 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>La presente invención se relaciona con la biotecnología y específicamente con el campo de la salud humana. Proporciona nuevas composiciones vacunales que comprende como principio activo un sistema que contiene al EGF humano recombinante, o péptidos de este y una proteína o péptido transportador, unidas a un núcleo constituido por nano-partículas inorgánicas, con dimensiones en escala nano o submicrométrica. Estas composiciones vacunales son útiles para el tratamiento crónico del cáncer y tiene como ventaja que no tienen efectos adversos en el sitio de la inyección y no se acumulan en el organismo.</p>
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000032A CU20200032A7 (es) | 2020-06-09 | 2020-06-09 | Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer |
| EP21761969.1A EP4162949A2 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
| AU2021294904A AU2021294904B2 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
| CA3180605A CA3180605A1 (en) | 2020-06-09 | 2021-05-31 | Vaccine compositions based on inorganic nanoparticles for cancer treatment |
| US17/928,806 US20230226163A1 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
| CN202180041521.XA CN116033918A (zh) | 2020-06-09 | 2021-05-31 | 用于治疗癌症的基于无机纳米颗粒的疫苗组合物 |
| BR112022024495A BR112022024495A2 (pt) | 2020-06-09 | 2021-05-31 | Composições de vacina baseadas em nanopartículas inorgânicas para tratamento de câncer |
| PCT/CU2021/050005 WO2021259397A2 (es) | 2020-06-09 | 2021-05-31 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer |
| JP2022575761A JP7623657B2 (ja) | 2020-06-09 | 2021-05-31 | がん治療のための無機ナノ粒子をベースとしたワクチン組成物 |
| KR1020227046420A KR20230022891A (ko) | 2020-06-09 | 2021-05-31 | 무기 나노입자를 기초로 한 암치료용 백신 조성물 |
| MX2022015460A MX2022015460A (es) | 2020-06-09 | 2021-05-31 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cancer. |
| TW110120236A TW202214288A (zh) | 2020-06-09 | 2021-06-03 | 用於癌症治療的以無機奈米粒子為底質之疫苗組成物 |
| ARP210101535A AR122547A1 (es) | 2020-06-09 | 2021-06-04 | Composiciones vacunales basadas en nano-partículas inorgánicas para el tratamiento del cáncer |
| CONC2022/0019141A CO2022019141A2 (es) | 2020-06-09 | 2022-12-28 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000032A CU20200032A7 (es) | 2020-06-09 | 2020-06-09 | Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20200032A7 true CU20200032A7 (es) | 2022-01-13 |
Family
ID=77518870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000032A CU20200032A7 (es) | 2020-06-09 | 2020-06-09 | Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230226163A1 (es) |
| EP (1) | EP4162949A2 (es) |
| JP (1) | JP7623657B2 (es) |
| KR (1) | KR20230022891A (es) |
| CN (1) | CN116033918A (es) |
| AR (1) | AR122547A1 (es) |
| AU (1) | AU2021294904B2 (es) |
| BR (1) | BR112022024495A2 (es) |
| CA (1) | CA3180605A1 (es) |
| CO (1) | CO2022019141A2 (es) |
| CU (1) | CU20200032A7 (es) |
| MX (1) | MX2022015460A (es) |
| TW (1) | TW202214288A (es) |
| WO (1) | WO2021259397A2 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2261433A1 (en) * | 1993-12-09 | 1995-06-10 | Belinda Sanchez Ramirez | Composition comprising autologous epidermal growth factor |
| CA2137639C (en) * | 1993-12-09 | 1999-01-26 | Agustin B. L. Davila | Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases |
| US8333996B2 (en) | 1995-05-19 | 2012-12-18 | Etex Corporation | Calcium phosphate delivery vehicle and adjuvant |
| CA2361421A1 (en) * | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| CU23077A1 (es) * | 2000-12-06 | 2005-08-17 | Centro Inmunologia Molecular | Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas |
| WO2003088925A2 (en) * | 2002-04-18 | 2003-10-30 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
| CU23652A1 (es) * | 2007-06-29 | 2011-05-27 | Centro Inmunologia Molecular | Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención |
| US20180353598A1 (en) * | 2015-09-17 | 2018-12-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | Optimization of physiological properties of calcium phosphate as vaccine adjuvant |
| CN107050447B (zh) * | 2016-11-14 | 2018-08-28 | 陕西诺威利华生物科技有限公司 | 猪流行性腹泻病毒灭活疫苗及其制备方法 |
| WO2020051566A1 (en) * | 2018-09-07 | 2020-03-12 | Immunotope, Inc. | Vaccines with enhanced immune response and methods for their preparation |
| WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
-
2020
- 2020-06-09 CU CU2020000032A patent/CU20200032A7/es unknown
-
2021
- 2021-05-31 BR BR112022024495A patent/BR112022024495A2/pt unknown
- 2021-05-31 EP EP21761969.1A patent/EP4162949A2/en active Pending
- 2021-05-31 JP JP2022575761A patent/JP7623657B2/ja active Active
- 2021-05-31 AU AU2021294904A patent/AU2021294904B2/en active Active
- 2021-05-31 CA CA3180605A patent/CA3180605A1/en active Pending
- 2021-05-31 US US17/928,806 patent/US20230226163A1/en active Pending
- 2021-05-31 MX MX2022015460A patent/MX2022015460A/es unknown
- 2021-05-31 WO PCT/CU2021/050005 patent/WO2021259397A2/es not_active Ceased
- 2021-05-31 KR KR1020227046420A patent/KR20230022891A/ko active Pending
- 2021-05-31 CN CN202180041521.XA patent/CN116033918A/zh active Pending
- 2021-06-03 TW TW110120236A patent/TW202214288A/zh unknown
- 2021-06-04 AR ARP210101535A patent/AR122547A1/es unknown
-
2022
- 2022-12-28 CO CONC2022/0019141A patent/CO2022019141A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4162949A2 (en) | 2023-04-12 |
| AU2021294904A1 (en) | 2023-02-02 |
| CN116033918A (zh) | 2023-04-28 |
| CA3180605A1 (en) | 2021-12-30 |
| JP7623657B2 (ja) | 2025-01-29 |
| JP2023529895A (ja) | 2023-07-12 |
| CO2022019141A2 (es) | 2022-12-30 |
| TW202214288A (zh) | 2022-04-16 |
| MX2022015460A (es) | 2023-02-01 |
| AU2021294904B2 (en) | 2025-04-10 |
| WO2021259397A2 (es) | 2021-12-30 |
| AR122547A1 (es) | 2022-09-21 |
| KR20230022891A (ko) | 2023-02-16 |
| WO2021259397A3 (es) | 2022-04-14 |
| BR112022024495A2 (pt) | 2023-01-24 |
| US20230226163A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001502A2 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción heterobiarilo, conjugados de estos y métodos y usos de estos | |
| Irache et al. | Nanomedicine: novel approaches in human and veterinary therapeutics | |
| BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
| CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| CL2017003458A1 (es) | Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| CO6390075A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| BR112012027055A8 (pt) | agente estabilizante para proteínas farmacêuticas. | |
| BR112012016021A8 (pt) | Formulações estáveis para liofilização de partículas terapêuticas | |
| CO2020008308A2 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| TR201908291T4 (tr) | Şifrelenmiş bir tümör antijeninin ekspresyonunun arttırılmasına yönelik bir histon sap-ilmiği ve bir poli(a) sekansı veya bir poliadenilasyon sinyali içeren veya bunun için kodlama yapan nükleik asit. | |
| MX2015015071A (es) | Proteinas péptidos y métodos de uso de las plantas antifúngicas. | |
| HK1208162A1 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| MX2015016155A (es) | Formulaciones en gel para dirigir la radioterapia. | |
| BRPI0705488A (pt) | composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem | |
| MX2011000047A (es) | Uso de factores de crecimiento recombinantes derivados de plantas en el cuidado de la piel. | |
| MX374958B (es) | Sal de cloruro de tat-nr2b9c. | |
| PE20091964A1 (es) | Encapsulacion de agentes biologicamente activos | |
| MX386234B (es) | Vacuna para la malaria. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| AR092529A1 (es) | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento | |
| BR112019011070A2 (pt) | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| EA201690085A1 (ru) | Полимерные наночастицы доцетаксела для лечения рака | |
| MX2017001012A (es) | Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo. |